New publications by µBONE researchers

Anna Dubrovska and Liza Gorodetska from Dresden found a promising blood-based biomarker for early detection of prostate cancer metastatic disease

Metastatic prostate cancer (PCa) presents significant treatment challenge due to heterogeneous responses to standard therapies and a lack of reliable predictive biomarkers. Our study elucidates a critical interplay between ALDH1A1/A3, TGF-β1, and MMP11 in PCa progression, revealing that ALDH1A1, through retinoic acid (RA) signaling, enhances TGF-β1 expression, subsequently regulating MMP11 expression and promoting metastatic dissemination and therapy resistance. We demonstrate that plasma MMP11 levels serve as a promising prognostic biomarker for metastatic PCa, exhibiting high specificity and sensitivity, and contribute to an ALDH1A1/MMP11-related plasma proteome signature correlating with clinical outcomes. These findings underscore the potential of MMP11 as a blood-based biomarker for early detection and personalized treatment strategies in advanced PCa, offering a novel avenue for improving patient outcomes.

This study is the result of a great collaboration between µBONE researchers Anna Dubrovska, Mechthild Krause, and Annett Linge and the team of Aldo Leal-Egaña.